Amgen (AMGN) Tops Q3 EPS by 47c; offers guidance

Amgen (NASDAQ: AMGN) reported Q3 EPS of $5.58, $0.47 better than the analyst estimate of $5.11. Revenue for the quarter came in at $8.5 billion versus the consensus estimate of $8.51 billion.

GUIDANCE:

Amgen sees FY2024 EPS of $19.20-$20.00, versus the consensus of $19.51. Amgen sees FY2024 revenue of $33-33.8 billion, versus the consensus of $33.2 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• UBS Upgrades Kaiser Aluminum Corporation (KALU) to Buy
• Jefferies Upgrades Zhejiang Dingli Machinery (603338:CH) to Buy
• Goldman Sachs Upgrades Capstone Copper Corp (CS:CN) (CSFFF) to Buy